Form 4: Steve Elms, ADMA Biologics Director, Sells Shares in Multiple Transactions

Director Steve Elms sold ADMA Biologics shares in multiple transactions between March 13 and March 15, 2024.

Summary

• Steve Elms, a director of ADMA Biologics, sold shares of common stock in a series of transactions.
• On March 13, 2024, he sold 407,000 shares at a weighted average price of $6.21, with prices ranging from $6.13 to $6.27.
• On March 14, 2024, he sold 448,276 shares at a weighted average price of $6.05, with prices ranging from $6.02 to $6.20.
• On March 15, 2024, he sold 183,008 shares at a weighted average price of $6.01, with prices ranging from $6.00 to $6.06.
• Following these transactions, Mr. Elms directly owns 76,441 shares, including 24,040 restricted stock units (RSUs) that vest in two equal installments over the next year, and indirectly owns 2,577,387 shares through Aisling Capital II LP.
• Mr. Elms disclaims beneficial ownership of Aisling's investment except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While insider sales are not inherently negative, a director selling a significant number of shares can create uncertainty among investors.

Negatives

• A director selling a significant number of shares could be interpreted negatively by the market.

Risks

• Continued selling by insiders could put downward pressure on the stock price.

Industry Context

Insider sales are a common occurrence, but the market often scrutinizes them for signals about a company's prospects. It's important to consider the context of these sales, such as the director's overall holdings and the company's performance.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price.
• The sales could influence investor confidence in the company's future prospects.

Key Dates